The current trial seeks to evaluate the role of the ExoDx Prostate test in men with low and favorable intermediate prostate cancer undergoing an active surveillance regimen.
Age
45–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male, 45+ years of age diagnosed with low-grade or favorable-intermediate prostate cancer and on an active surveillance regimen
You may not be if
Clinical symptoms of urinary tract infection at time of enrollment.
History of invasive treatment for benign prostatic hypertrophy with in 6 months of enrollment.
Known hepatitis or HIV
History of concurrent renal/bladder tumors
Clareo Health | ExoDx Prostate Evaluation in Active Surveillance Patient Population
